Company: REVB
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034584
Chunk: 235

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 1B
Chunk 235
---
 up to 17 shares of common stock with an exercise price of $45,070.73 per share which expire on January 31, 2027, valued on the issuance date in the aggregate at $326,675 (the “Rollover Warrants”). As of December 31, 2024, there were 7 Rollover Warrants remaining to be exercised or exchanged.The fair value of the Rollover Warrants were estimated using the Black-Scholes option pricing model with the following assumptions: 

        Volatility

        115
        %

        Expected term (years)

        6

        Risk-free interest rate

        0.85
        %

        Expected dividend yield

        0.0
        %
       
      Class A Common Stock WarrantsIn connection with the closing of a private placement on January 25, 2022 (“PIPE Investment”), the Company issued warrants to an institutional investor to purchase up to 154 shares of common stock at an exercise price of $55,272.00 per share (the “Class A Common Stock Warrants”), valued on the PIPE Investment purchase date in the aggregate at $3.6 million and included in the issuance costs of the PIPE Investment and treated as equity. The warrants were exercisable immediately upon issuance, provide for a cash or cashless exercise right and expire on July 25, 2027.The fair value of the Class A Common Stock Warrants were estimated using the Black-Scholes option pricing model with the following assumptions: 

        Volatility

        47
        %

        Expected term (years)

        5

        Risk-free interest rate

        1.54
        %

        Expected dividend yield

        0.0
        %
       
      Class A Placement Agent Common Stock WarrantsIn connection with the PIPE Investment, the Company issued warrants to Roth to purchase an aggregate of 22 shares of common stock at an exercise price of $55,272.00 per share (the “Class A Placement Agent Common Stock Warrants”), valued on the PIPE Investment purchase date in the aggregate at $0.5 million and included in the issuance costs of the PIPE Investment and treated as equity. The warrants were exercisable immediately upon issuance, provide for a cash or cashless exercise right and expire on July 25, 2027.

 F-22

The fair value of the Class A Placement Agent Common Stock Warrants were estimated using the Black-Scholes option pricing model with the following assumptions: